Application of ginkgolic acid in preparation of medicine for preventing and/or treating diseases caused by overactivity of osteoclast

A technology of osteoclasts and ginkgolic acid, applied in bone diseases, drug combinations, antipyretics, etc.

Inactive Publication Date: 2015-06-03
FUDAN UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are few reports on its active ingredients and therapeutic efficacy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginkgolic acid in preparation of medicine for preventing and/or treating diseases caused by overactivity of osteoclast
  • Application of ginkgolic acid in preparation of medicine for preventing and/or treating diseases caused by overactivity of osteoclast
  • Application of ginkgolic acid in preparation of medicine for preventing and/or treating diseases caused by overactivity of osteoclast

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Dose-effect relationship of ginkgolic acid (C17:1) inhibiting NFATc1 nuclear translocation

[0028] Principle: The high-content instrument can quantitatively detect the fluorescence changes in the cytoplasm and nucleus. NFATc1 in the EGFP-NFATc1-U2OS stably transfected cell line has been labeled with green fluorescent protein (GFP), so the distribution of NFATc1 can be judged according to the fluorescence changes in the cytoplasm and nucleus and the cell picture, so as to determine its nuclear entry quantity. Carbachol was used as the stimulator of NFATc1 translocation into the nucleus, and the optimal stimulation time and dose were determined first in the preliminary experiment.

[0029] Methods: EGFP-NFATc1U2OS cells were inoculated in 96-well plates to culture cells, firstly treated with 6.25, 12.5, 25, 50 μM ginkgolic acid (C17:1) (YXS) for 2 hours, then treated with 2 μM carbachol for 30 min, the cells were fixed and used After the nuclei were stained wi...

Embodiment 2

[0030] Example 2: Inhibitory effect of ginkgolic acid (C17:1) on RANKL-induced nuclear translocation of NFATc1 in osteoclast precursor cells

[0031] Principle: The RANKL pathway is considered to be a key pathway in the process of osteoclast differentiation and formation. Intracellular calcium fluctuations directly induced by RANKL lead to phosphorylation of intracellular calcineurin kinase, which selectively activates NFATc1 and promotes its translocation into the nucleus, thereby initiating NFATc1-dependent gene expression during osteoclast differentiation. In the absence of NFATc1, osteoclasts cannot differentiate into osteoclasts even if the RANKL pathway is normally activated.

[0032] Methods: Osteoclast precursor cells RAW264.7 cells were seeded in medium cell culture dishes and treated with 50ng / ml RANKL and 0, 6.25, 12.5, 25M ginkgolic acid (C17:1) (YXS) for two days. The nuclear protein isolation kit was used to extract nuclear protein, cytoplasmic protein, and tota...

Embodiment 3

[0034] Example 3: Inhibitory effect of ginkgolic acid (C17:1) on osteoclast differentiation

[0035] Principle: Under the continuous stimulation of macrophage colony-stimulating factor (M-CSF) and RANKL, bone marrow mononuclear cells contact each other and fuse to form multinucleated cells, and differentiate to form mature osteoclasts with a seal ring structure, and secrete osteoclasts. The characteristic enzyme of bone cells is tartrate-resistant acid phosphatase (TRAP), and the number of osteoclasts can be detected by staining for TRAP.

[0036] Methods: Bone marrow mononuclear cells were isolated from the femur of C57 / BL6 mice, and the cell density was adjusted to 100,000 / mL after counting, and 30 ng / mL of recombinant mouse macrophage colony-stimulating factor (M-CSF) was added and inoculated in 96 Well culture plate, add 100 μL to each well. On the second day, the cells were induced with RANKL at a concentration of 50ng / mL, and 0, 3.125, 6.25, 12.5, and 25 μM ginkgolic ac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, relates to novel pharmaceutical application of ginkgolic acid and particularly relates to application of ginkgolic acid (C17:1), which is a syzygiumtetragonum extract having a structural formula show in the specification, in preparation of a medicine for preventing and / or treating diseases caused by overactivity of osteoclast. The ginkgolic acid (C17:1) is capable of preventing nuclear translocation of NFATc1 and inhibiting differentiation and bone erosion of osteoclast and thus is used for preparing the medicine for preventing and treating the diseases including osteoporosis, osteolysis, rheumatoid arthritis, multiple myeloma, Paget's disease, hypercalcemia of tumors, osteogenesis imperfect, alveolar bone deficiency or bone loss caused during immunosuppressive therapy or long-term use of glucocorticoid.

Description

technical field [0001] The invention belongs to the field of medicaments and relates to a new medicinal application of ginkgolic acid. It specifically relates to the application of ginkgolic acid (C17:1) extracted from apple apples in the preparation of medicines for preventing and / or treating diseases caused by excessive activation of osteoclasts. The ginkgolic acid (C17:1) inhibits osteoclast differentiation and bone erosion by preventing NFATc1 nuclear translocation, and is used for the prevention and treatment of osteoporosis, osteolysis, rheumatoid arthritis, multiple myeloma, Paget's Diseases, hypercalcemia of malignant tumors, osteogenesis imperfecta, alveolar bone loss, or bone loss caused by immunosuppressive treatment or long-term use of glucocorticoids. Background technique [0002] Studies have shown that osteoclasts are polar multinucleated cells derived from a myeloid lineage with the ability to resorb bone. Osteoclasts attached to the bone surface create an ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/60A61P19/10A61P19/02A61P29/00A61P19/08A61P35/00
Inventor 沈晓燕尹胜周春张馨文朱翰东
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap